Results 21 to 30 of about 1,538,497 (307)

Travel and Oral Anticoagulation [PDF]

Journal of Travel Medicine, 2009
Millions of individuals worldwide are on permanent or temporary oral anticoagulation treatment with vitamin K antagonists (VKAs). The effectiveness of VKAs has been established by clinical trials for several indications. Among these, the primary or secondary prevention of venous thromboembolism, the prevention of systemic embolism in patients with ...
Jürgen, Ringwald, Julian, Strobel, Reinhold, Eckstein   +2 more
openaire   +2 more sources

Selected attributes of oral anticoagulants.

, 2021
Selected attributes of oral anticoagulants.
Yang Hu (315392), Vincent K. C. Yan (10008623), Marco K. H. Cheung (11337997), Esther W. Chan (8190144), Carlos K. H. Wong (8190138), Jiaxi Zhao (1431664), Hung-Fat Tse (351982), Xue Li (285380), Gregory Y. H. Lip (7429799), Chung-Wah Siu (351983), Yutao Guo (696123), Hao Wang (39217)   +11 more
core   +1 more source

Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review

Рациональная фармакотерапия в кардиологии, 2022
The last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers ...
B. A. Tatarsky, N. V. Kazennova
doaj   +1 more source

Oral Anticoagulation Thresholds [PDF]

Circulation, 2001
Background Monitoring patients on oral anticoagulation is essential to prevent hemorrhage and recurrent thrombosis. We studied tissue factor–induced whole-blood coagulation in patients on warfarin therapy with similar international ...
K E, Brummel, S G, Paradis, R F, Branda, K G, Mann   +3 more
openaire   +2 more sources

Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]

, 2017
A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Curto Aguilera, Adrián, Albaladejo Martínez, Alberto Francisco, Alvarado Lorenzo, Alfonso, Albaladejo Martínez, Alberto   +3 more
core   +1 more source

Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?

Российский кардиологический журнал, 2019
Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with ...
N. N. Kryukov, E. V. Sayutina, A. M. Osadchuk, M. A. Osadchuk   +3 more
doaj   +1 more source

Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants

, 2021
Background: Patient's adherence to oral anticoagulant therapy is essential to prevent and treat thrombotic events. Methods: To assess the patients' adherence Morisky Medication Adherence Scale 8-items was used.
Perra F., Marongiu F., Barcellona D., Cornacchini S., Farci N., Diovaldi M., Moledda V., Mameli A., Nicola Farci, Marina Diovaldi, Doris Barcellona, Francesco Marongiu, Antonella Mameli, Valentina Moledda, Flaminia Perra, Simona Cornacchini   +15 more
core   +1 more source

Complications of Pharmacotherapy with New Oral Anticoagulants Caused by Inter-Drug Interactions: Focus on Gastrointestinal Bleeding

Безопасность и риск фармакотерапии, 2019
New oral  anticoagulants are  effective for  the  prevention of thromboembolic complications in patients with atrial fibrillation, or after orthopedic surgery.
A. P. Pereverzev, O. D. Ostroumova, O. N. Tkacheva, Yu. V. Kotovskaya   +3 more
doaj   +1 more source

Gastrointestinal protection options for direct oral anticoagulants in patients with atrial fibrillation

, 2022
Gastrointestinal bleeding (GIB) associated with the use of direct oral anticoagulants or, as they are also called, new oral anticoagulants (NOAC) is a serious medical problem, the relevance of which will only increase taking into account the constant ...
Natalya M. Vorobyeva, Olga N. Tkacheva, Irina P. Malaya, Alexandra M. Lelkova   +3 more
core   +1 more source

Oral anticoagulants: Optimizing venous thromboembolism management

Journal of Applied Hematology, 2019
A decade ago, oral anticoagulants were limited to Vitamin K antagonists, i.e., warfarin. Since 2010, the US Food and Drug Administration has approved several non-Vitamin K oral anticoagulants: dabigatran is a direct thrombin inhibitor, while apixaban ...
Fahad A S. Aleidan
doaj   +1 more source